pneumonia
remain
among
top
common
caus
mortal
age
group
unit
state
common
infecti
caus
mortal
unit
state
pneumonia
respons
million
hospit
admiss
death
pneumonia
commonli
caus
viral
bacteri
pathogen
former
respons
case
clinic
sign
symptom
associ
two
etiolog
often
indistinguish
physic
examin
routin
microbiolog
test
respiratori
sampl
radiolog
find
routin
reliabl
establish
accur
diagnosi
bacteri
pneumonia
develop
diagnost
may
assist
allevi
situat
arisen
polymeras
chain
reaction
pcr
technolog
adopt
clinic
use
rapid
identif
variou
pathogen
multiplex
pcr
technolog
recent
ad
allow
identif
panel
potenti
respiratori
pathogen
contrast
older
pcr
technolog
identifi
singl
target
biomark
examin
diagnost
util
anoth
approach
differenti
bacteri
infect
type
inflammatori
state
biomark
creactiv
protein
erythrocyt
sediment
rate
often
elev
infecti
noninfecti
condit
procalcitonin
pct
level
routin
elev
presenc
bacteri
infect
remain
low
set
type
inflammatori
process
use
test
decis
tool
establish
safe
method
rule
bacteri
infect
thu
reduc
antibiot
use
howev
low
serum
level
pct
suggest
absenc
bacteri
infect
exclud
therefor
result
alway
use
conjunct
clinic
judgment
particular
caution
given
interpret
result
serious
ill
patient
despit
advanc
clinic
applic
diagnost
technolog
report
mani
patient
nonetheless
continu
receiv
antibiot
therapi
without
regard
posit
viral
pcr
andor
low
pct
result
object
determin
frequenc
chang
empir
antibiot
therapi
known
proven
case
pneumonia
result
respiratori
panel
rp
andor
pct
test
known
clinician
thu
determin
need
activ
stewardship
intervent
institut
retrospect
singlecent
studi
perform
medic
univers
south
carolina
hospit
bed
tertiari
quaternari
academ
medic
center
averag
daili
censu
rate
annual
admiss
averag
adult
inpati
length
stay
age
casemix
index
day
year
respect
hospit
casemix
index
repres
averag
diagnosisrel
group
drg
rel
weight
hospit
calcul
sum
drg
weight
medicar
discharg
divid
number
discharg
use
determin
alloc
resourc
care
andor
treat
patient
group
studi
review
approv
institut
review
board
institut
articl
contain
new
studi
human
anim
subject
perform
author
record
access
patient
year
age
older
proven
suspect
respiratori
infect
indic
pcr
respiratori
bacteri
cultur
intern
statist
classif
diseas
relat
health
problem
revis
code
acut
infecti
respiratori
ill
code
associ
hospit
januari
januari
patient
record
evalu
requir
rp
pct
within
first
h
present
patient
cystic
fibrosi
base
patient
posit
bacteri
cultur
exclud
addit
patient
copd
chronic
bronchiti
emphysema
exclud
lack
util
pct
distinguish
viral
bacteri
respiratori
ill
copd
describ
basic
studydesign
flow
illustr
fig
procalcitonin
concentr
determin
vida
brahm
pct
autom
test
marci
franc
pct
report
sensit
specif
distinguish
bacteri
infect
inflammatori
process
routin
laboratori
report
denot
valu
suggest
bacteri
infect
unlik
pct
test
gener
avail
within
two
hour
specimen
obtain
presenc
respiratori
virus
determin
filmarray
respiratori
panel
biofir
diagnost
inc
salt
lake
citi
ut
usa
multiplex
pcr
test
test
detect
virus
includ
adenoviru
coronaviru
coronaviru
coronaviru
coronaviru
human
metapneumoviru
influenza
influenza
subtyp
influenza
subtyp
influenza
subtyp
influenza
b
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
rhinovirusenteroviru
respiratori
syncyti
viru
result
avail
one
hour
specimen
obtain
sensit
specif
respect
institut
protocol
guidanc
useinterpret
pct
place
time
studi
neither
test
educ
provid
use
implement
analysi
period
specif
antimicrobi
stewardship
activ
initi
place
specif
test
studi
patient
data
collect
includ
age
sex
comorbid
condit
diagnos
intens
care
unit
admiss
antibiot
use
durat
result
bacteri
cultur
obtain
pct
rp
drug
order
evalu
discontinu
therapi
within
h
procalcitonin
posit
viral
result
data
analyz
descript
analysi
perform
excel
microsoft
redmond
wa
usa
figur
creat
use
excel
inkscap
free
softwar
foundat
inc
boston
usa
individu
patient
record
pct
andor
rp
result
met
inclus
studi
fig
result
pct
rp
test
avail
patient
respect
patient
test
perform
first
h
result
suggest
patient
may
opportun
antibiot
avoid
total
patient
pct
posit
pcr
identifi
patient
test
result
first
h
antibiot
administ
patient
period
tabl
frequent
detect
respiratori
virus
influenza
ab
total
rhinovirusenteroviru
fig
patient
prescrib
antibiot
within
first
h
antibiot
discontinu
within
h
laboratori
result
patient
either
pct
posit
pcr
tabl
median
durat
antibiot
day
group
rang
day
day
day
pct
posit
rp
respect
problem
inappropri
use
antibiot
lead
antibioticresist
organ
overst
issu
escal
nation
recogn
address
white
hous
nation
action
plan
combat
antibioticresist
bacteria
among
initi
call
increas
antimicrobi
stewardship
activ
judici
use
antimicrobi
innov
rapid
diagnost
facilit
effort
outpati
set
includ
emerg
depart
major
antibiot
prescrib
patient
present
respiratori
condit
mani
infect
viral
origin
includ
nearli
pneumonia
turn
much
antibiot
prescrib
respiratori
infect
outpati
unwarr
unnecessari
antibiot
use
hospit
patient
appar
respiratori
tract
infect
also
occur
overus
explain
larg
extent
inher
difficulti
clinic
differenti
bacteri
viral
infect
time
appear
treatment
respiratori
tract
infect
repres
major
area
opportun
judici
limit
use
antibiot
util
rapid
diagnost
test
may
help
differenti
use
pct
rp
alon
combin
success
safe
use
guid
diagnosi
therapi
number
studi
shown
pct
effect
test
util
alter
antibiot
prescrib
pattern
without
advers
affect
patient
outcom
studi
empir
antibiot
therapi
strongli
discourag
andor
recommend
discontinu
patient
low
pct
level
similar
use
pct
rule
bacteri
infect
posit
result
rp
shown
use
effort
reduc
antibiot
use
provid
direct
proof
viral
respiratori
infect
afzal
colleagu
use
rp
result
led
reduct
antibiot
durat
inform
made
avail
primari
care
provid
patient
posit
viral
rp
disclos
primari
care
provid
n
median
durat
antibiot
day
oppos
day
p
patient
proven
bacteri
infect
n
furthermor
posit
viral
pcr
disclos
n
median
durat
antibiot
bacteri
infect
group
find
decreas
antibiot
exposur
base
viral
pcr
also
report
oosterheert
colleagu
studi
posit
pr
result
led
discontinu
antibiot
patient
one
potenti
challeng
relianc
rapid
test
rule
bacteri
infect
coinfect
viral
bacteri
pathogen
report
case
infecti
pneumonia
coinfect
recent
explor
musher
colleagu
studi
analyz
etiolog
communityacquir
pneumonia
cap
cohort
hospit
cap
patient
us
veteran
administr
hospit
found
coinfect
viru
bacterium
fungu
howev
case
viral
infect
document
bacteri
coinfect
patient
sever
cap
requir
mechan
ventil
coinfect
may
occur
often
studi
karhu
colleagu
coinfect
found
patient
importantli
investig
report
pct
concentr
actual
help
distinguish
bacteri
nonbacteri
infect
within
bacterialvir
coinfect
patient
median
admiss
peak
pct
concentr
respect
valu
viral
infect
group
respect
data
consist
previou
pct
data
suggest
result
effect
discrimin
viral
bacteri
infect
howev
note
mani
aforement
studi
establish
pct
safe
effect
way
rule
bacteri
infect
other
cast
doubt
sensit
one
group
report
sensit
approxim
biomark
may
role
improv
use
test
studi
clinicianprescrib
behavior
institut
rp
andor
pct
laboratori
result
avail
prescrib
physician
suggest
pure
viral
respiratori
infect
observ
antibiot
discontinu
rate
patient
posit
viral
rp
result
pct
patient
test
result
avail
n
highli
suggest
pure
viral
infect
antibiot
discontinu
rate
even
lower
one
possibl
explan
low
rate
antibiot
discontinu
could
relat
rel
low
prescrib
antibiot
patient
proven
suspect
respiratori
infect
either
low
pct
posit
viral
rp
result
believ
rel
low
incid
prescrib
context
suggest
mani
prescrib
avoid
antibiot
therapi
base
clinic
factor
suggest
nonbacteri
ill
caus
respiratori
symptom
earlier
studi
falsey
colleagu
respiratori
ill
reflect
similar
result
substanti
opportun
judici
antimicrobi
use
base
result
rp
pct
singlecent
studi
patient
deem
pure
viral
infect
viral
test
posit
bacteri
test
neg
serum
pct
level
admiss
day
two
hospit
durat
inpati
antibiot
found
significantli
less
viral
alon
group
compar
mix
group
mean
vs
day
respect
data
suggest
opportun
use
combin
rp
pct
result
narrow
etiolog
diagnosi
perhap
decreas
unnecessari
antibiot
exposur
mix
infect
note
patient
util
diagnost
batteri
appear
distinguish
pure
viral
infect
also
notabl
howev
rp
pct
result
suggest
pure
viral
infect
result
shorter
durat
antibiot
therapi
averag
durat
therapi
extend
day
beyond
avail
result
rp
pct
test
recent
followup
studi
antibiot
prescrib
pattern
associ
low
pct
posit
viral
rp
result
patient
nonpneumon
lower
respiratori
tract
infect
character
two
group
patient
one
receiv
standard
care
second
receiv
care
specifi
use
pct
algorithm
viral
test
investig
observ
antibiot
discontinu
rate
pct
posit
viral
rp
report
substanti
differ
antibiot
discontinu
rate
observ
sever
differ
studi
method
like
explain
dispar
result
importantli
nonpneumon
appar
defin
clinic
suggest
symptom
lower
respiratori
tract
infect
clear
evid
risk
factor
bacteri
pneumonia
previou
studi
conduct
institut
recent
studi
method
result
studi
share
medic
staff
prior
commenc
latter
studi
sourc
intern
bia
like
introduc
would
influenc
antibiot
usagediscontinu
rate
observ
usagediscontinu
rate
differ
compar
group
may
substanti
impress
time
studi
proactiv
intervent
second
provid
evid
proactiv
intervent
beyond
avail
rapid
diagnost
test
result
influenc
prescrib
behavior
studi
without
limit
retrospect
singlecent
studi
prescrib
behavior
observ
may
well
differ
institut
exclud
patient
chronic
obstruct
pulmonari
diseas
chronic
bronchiti
emphysema
cystic
fibrosi
result
gener
relev
respiratori
tract
infect
patient
popul
criteria
antibiot
prescrib
base
sole
upon
avail
valu
three
specif
test
pct
rp
bacteri
cultur
patient
may
indic
suggest
bacteri
pulmonari
infect
sever
ill
indic
sign
symptom
imag
studi
elev
white
cell
urinari
bacteri
antigen
would
like
influenc
decis
usecontinu
antibiot
therapi
account
influenc
evid
prescrib
pattern
analysi
potenti
impact
obviou
import
addit
evalu
time
antibiot
administr
relat
time
avail
pct
rp
test
result
earli
test
optim
ensur
appropri
therapi
decis
howev
studi
prorata
use
higher
pct
level
determin
appropri
antibiot
discontinu
data
suggest
regardless
time
administr
antibiot
conserv
pct
level
would
suggest
opportun
appropri
antibiot
discontinu
moreov
pct
level
use
evalu
antibiot
avoid
discontinu
consist
studi
involv
pct
guidanc
therapi
possibl
proven
respiratori
tract
infect
final
fulli
character
true
impact
pct
pcr
antibiot
prescrib
comparison
would
need
includ
patient
pcr
pct
result
patient
result
suggest
monomicrobi
viral
respiratori
infect
believ
sever
potenti
clinic
implic
find
patient
proven
presum
respiratori
tract
infect
patient
rp
pct
test
challeng
coinfect
virus
bacteria
denot
need
respiratori
infect
protocol
includ
pct
rp
test
order
emerg
depart
upon
admiss
ensur
prompt
result
assist
clinic
decisionmak
process
appropri
use
antibiot
combin
use
test
upon
admiss
could
decreas
antibiot
use
averag
day
patient
studi
posit
viral
rp
pct
given
issu
pct
sensit
would
appear
prudent
test
employ
low
rate
antibiot
discontinu
set
posit
viral
rp
pct
result
appear
need
educ
provid
educ
includ
review
etiolog
respiratori
tract
infect
provid
pct
test
interpret
inform
need
judici
use
antibiot
relat
potenti
complic
resist
develop
final
opportun
antimicrobi
stewardship
program
asp
asp
provid
educ
practition
develop
antibiot
guidelin
pctrp
algorithm
proactiv
recommend
antibiot
discontinu
base
upon
proper
interpret
pct
rp
test
result
proactiv
intervent
provid
asp
import
ensur
meaning
use
rapid
diagnost
oppos
lack
clinic
benefit
absenc
aspfacilit
intervent
find
suggest
pct
rp
result
alon
combin
indic
diagnosi
pure
viral
respiratori
infect
infrequ
associ
discontinu
antibiot
therapi
institut
demonstr
prescrib
behavior
suggest
possibl
opportun
antimicrobi
stewardship
develop
clinic
pathway
decis
tool
provis
relev
educ
import
test
well
direct
intervent
clinician
goal
lessen
unnecessari
antibiot
use
addit
studi
evalu
variat
antibiot
prescrib
combin
rp
pct
protocol
respiratori
tract
infect
along
stewardship
activ
provid
educ
respons
rp
pct
result
